143 related articles for article (PubMed ID: 7667607)
21. Should macroprolactin be measured in all hyperprolactinaemic sera?
McKenna TJ
Clin Endocrinol (Oxf); 2009 Oct; 71(4):466-9. PubMed ID: 19320649
[TBL] [Abstract][Full Text] [Related]
22. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients.
Kavanagh-Wright L; Smith TP; Gibney J; McKenna TJ
Clin Endocrinol (Oxf); 2009 Apr; 70(4):599-605. PubMed ID: 18771565
[TBL] [Abstract][Full Text] [Related]
23. Hyperprolactinaemia does not always mean 'hyperprolactinaemia'!
Gezer A; Atasü T; Hekim C; Stenman UH; Hekim N
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):206-8. PubMed ID: 15653204
[TBL] [Abstract][Full Text] [Related]
24. Macroprolactin; high molecular mass forms of circulating prolactin.
Fahie-Wilson MN; John R; Ellis AR
Ann Clin Biochem; 2005 May; 42(Pt 3):175-92. PubMed ID: 15949152
[TBL] [Abstract][Full Text] [Related]
25. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
26. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
27. Effects of anti-prolactin autoantibodies on serum prolactin measurements.
Hattori N; Ikekubo K; Ishihara T; Moridera K; Hino M; Kurahachi H
Eur J Endocrinol; 1994 May; 130(5):434-7. PubMed ID: 8180668
[TBL] [Abstract][Full Text] [Related]
28. Macroprolactin: what is it and what is its importance?
Sadideen H; Swaminathan R
Int J Clin Pract; 2006 Apr; 60(4):457-61. PubMed ID: 16620360
[TBL] [Abstract][Full Text] [Related]
29. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
Pinto LP; Hanna FW; Evans LM; Davies JS; John R; Scanlon MF
Clin Endocrinol (Oxf); 2003 Nov; 59(5):580-4. PubMed ID: 14616880
[TBL] [Abstract][Full Text] [Related]
30. Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia.
Fideleff HL; Ruibal G; Boquete H; Pujol A; Sequera A; Sobrado P
Horm Res; 2000; 53(1):16-9. PubMed ID: 10965215
[TBL] [Abstract][Full Text] [Related]
31. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up.
Hattori N; Ishihara T; Saiki Y; Shimatsu A
Clin Endocrinol (Oxf); 2010 Dec; 73(6):792-7. PubMed ID: 20874771
[TBL] [Abstract][Full Text] [Related]
32. Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus.
García M; Colombani-Vidal ME; Zylbersztein CC; Testi A; Marcos J; Arturi A; Babini J; Scaglia HE
Lupus; 2004; 13(8):575-83. PubMed ID: 15462486
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
[TBL] [Abstract][Full Text] [Related]
34. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
[TBL] [Abstract][Full Text] [Related]
35. Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
Zadrozna-Sliwka B; Bolanowski M; Kałuzny M; Syrycka J
Endokrynol Pol; 2007; 58(2):116-22. PubMed ID: 17578827
[TBL] [Abstract][Full Text] [Related]
36. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.
Cavaco B; Leite V; Santos MA; Arranhado E; Sobrinho LG
J Clin Endocrinol Metab; 1995 Aug; 80(8):2342-6. PubMed ID: 7629227
[TBL] [Abstract][Full Text] [Related]
37. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
38. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
39. Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.
Amadori P; Dilberis C; Marcolla A; Pinamonti M; Menapace P; Dal Bosco F
J Endocrinol Invest; 2003 Feb; 26(2):148-56. PubMed ID: 12739743
[TBL] [Abstract][Full Text] [Related]
40. Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia.
Sapin R; Gasser F; Grucker D
Clin Chim Acta; 2002 Feb; 316(1-2):33-41. PubMed ID: 11750272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
